Product Description
Mechanisms of Action: DNA Replication Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Poniard
Company Location: SAN FRANCISCO CA 94111
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Small Cell Lung Cancer
Phase 2: Lung Cancer|Colorectal Cancer|Prostate Cancer|Small Cell Lung Cancer
Phase 1: Head and Neck Cancer|Lung Cancer|Breast Cancer|Ovarian Cancer|Pancreatic Cancer|Death, Sudden, Cardiac|Cardiac Arrhythmias|Bladder Cancer|Heart Cancer|Colorectal Cancer|Gastrointestinal Cancer|Vascular Cancer|Digestive System Cancer|Prostate Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2007-000528-42 | P3 |
Completed |
Small Cell Lung Cancer |
2010-03-31 |
|
| NCT00478946 | P2 |
Unknown status |
Colorectal Cancer |
2009-12-01 |
|
| NCT00448734 | P2 |
Unknown status |
Prostate Cancer |
2009-12-01 |
|
| 0602 Oral Picoplatin | P1 |
Completed |
Digestive System Cancer|Head and Neck Cancer|Ovarian Cancer|Breast Cancer|Bladder Cancer|Gastrointestinal Cancer|Colorectal Cancer|Lung Cancer|Pancreatic Cancer|Prostate Cancer |
2009-07-01 |